Monthly Archives: June 2013
Evaluating the Xeloda and Tarceva Oral Regimen for Advanced Pancreatic Cancer
Spanish research Fulgar and colleagues published a recent article in the journal Anticancer Research detailing the results of their multi-center Phase 2 clinical trial evaluating oral erlotinib (Tarceva – 150 mg per day) coupled with the also orally administered capecitabine (Xeloda) in pancreatic cancer (ductal adenocarcinoma of the pancreas). Capecitabine is a pro-drug of 5-FU […]
Phase 2 Results of Gemcitabine and Monoclonal Antibody for Advanced Pancreatic Cancer
It’s hard to keep up with company changes in the biotech world, but a recent published study in the Annals of Oncology, the official journal of the European Society for Medical Oncology (ESMO) includes highly intriguing results of an unusual combination for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) of gemcitabine and the fully […]
Momordica Charantia (Bitter Melon) Juice Shows Promise with Pancreatic Cancer Cells and in Mice
Researchers from the University of California at San Diego have published a recent study in the journal Carcinogenesis that showed that Bitter Melon Juice (BMJ) caused cell death in four lines of pancreatic cancer cells, and appeared to inhibit pancreatic cancer tumor (ductal adenocarcinoma of the pancreas) activity in mice. The fruit of the vine […]
Phase 2 Results of Gemcitabine and Monoclonal Antibody for Advanced Pancreatic Cancer
It’s hard to keep up with company changes in the biotech world, but a recent published study in the Annals of Oncology, the official journal of the European Society for Medical Oncology (ESMO) includes highly intriguing results of an unusual combination for advanced pancreatic cancer (ductal adenocarcinoma of the pancreas) of gemcitabine and the fully […]
MicroRNA plus CA19-9 as a Diagnostic Marker for Pancreatic Cancer?
The search for a screening or diagnostic marker in pancreatic cancer (ductal adenocarcinoma of the pancreas) is paramount. If the disease could be found earlier, it is likely that serious inroads could be made into improved survival advantage for patients. Wang and associates at Fudan University in Shanghai, China published an intriguing article in April’s […]